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p53 Variants Predisposing to Cancer Are Present in
Healthy Centenarians
To the Editor:
Cancer results from the expansion of cell clones that
progressively lose control of proliferation, differentia-
tion, and death, owing to accumulation of mutational
events in genes that control the cell cycle and apoptosis.
Nuclear protein p53 is thought to play a major role in
malignancy, since it induces genes that determine apop-
tosis and cell-cycle arrest, interacts with proteins em-
ployed in DNA repair, and binds to DNA strand breaks.
As expected, somatic mutations in p53 are found in a
variety of human cancers. Mutations are predominantly
inactivating, thus eliminating the “guardian of the ge-
nome” from the proliferating cells. Germ-line mutations
of p53 also have been described as the molecular basis
of a rare familial cancer-prone syndrome, Li-Fraumeni
syndrome. At the population level, common variants
(polymorphisms) of p53 are present. In particular, a
CrG transversion leads to a proline-to-arginine change
at p53 codon 72. Several studies have reported data
regarding the association of the codon 72 variants with
susceptibility to a variety of human cancers, such as
breast cancer, lung cancer, and colorectal neoplasia (Bir-
gander et al. 1995; Sjalander et al. 1996). Some reports
suggest that Arg/Pro72 alleles should be considered as
markers in linkage disequilibrium with other sites able
to modulate cancer risk (Sjalander et al. 1995). Recently,
a new insight into the role of codon 72 in human cancers
has been reported by Storey et al. (1998). In their anal-
ysis, the authors found that a majority (76%) of women
affected by human papillomavirus (HPV)–induced cer-
vical carcinoma were homozygous for Arg72 alleles,
compared with a frequency of 37% among unaffected
women. In addition, when functional analysis of p53
variants was performed, the authors found that a p53
protein carrying an arginine at codon 72 binds more
effectively to HPV oncoprotein E6 and is degraded and
inactivated more rapidly by the proteasome pathway.
The result is an estimated sevenfold risk of developing
cervical cancer, for people homozygous for Arg72, when
infected by HPV that is able to produce E6 protein.
Overall, the available data in the literature suggest that
p53 variants may be considered as risk factors for some
of the major neoplastic diseases in humans, such as lung,
colorectal, breast, and cervical cancer, and are expected
to affect survival. Hence, an underrepresentation of p53
variants involved in cancer risk would be expected in a
group of people who reach very old age in good health
and who have escaped any overt cancer disease. Ac-
cordingly, healthy centenarians of both sexes were stud-
ied, to test this prediction, and the results were compared
with those obtained from the study of a group of
younger people.
The centenarians and the controls in our study were
basically those studied in a previous investigation, in
which significant differences in the frequency of apoli-
poprotein B (ApoB) VNTR alleles were found between
the two groups (De Benedictis et al. 1997). The sample
of centenarians comprised 176 healthy unrelated sub-
jects (53 males and 123 females) from northern and
southern Italy, and the health status of each was assessed
as described elsewhere (Capurso et al. 1997). The con-
trol group comprised 204 younger unrelated subjects
(113 males and 91 females, 20–60 years of age) ran-
domly collected from northern and southern Italy. The
ancestry in the specific geographic area of the subjects
included in this study was checked as far back as the
grandparental generation. In table 1 the frequencies of
p53 codon 72 alleles and genotypes in the younger con-
trols and the centenarians are shown. No difference be-
tween the two groups was found. Moreover, no differ-
ence in allelic and genotypic distributions, between the
centenarians and the younger controls, was found when
sex and geographic origin were considered in the analysis
or when the group of younger controls was split into
two subgroups (!40 and ≥40 years of age) (data not
shown).
Several explanations can account for the results re-
ported here. First, the most direct explanation is that
Arg/Pro72 alleles are neutral and do not exert any cen-
soring, with regard to susceptibility to cancer and life
expectancy. This hypothesis is compatible with the cau-
tious conclusions of a recent meta-analysis, which points
out that a consensus about the role of p53 variants in
human cancer has yet to be reached (Weston and God-
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Table 1
Allelic and Genotypic Frequencies of p53 Codon 72 Polymorphism
No. (%) of
Younger Controls
[ ]n  204
No. (%) of
Centenarians
[ ]n  176
p53 Allele:a
Pro72 128 (31.4) 101 (28.7)
Arg72 280 (68.6) 251 (71.3)
p53 Genotype:b
Pro72/Pro72 18 (8.8) 12 (6.8)
Arg72/Pro72 92 (45.1) 77 (43.8)
Arg72/Arg72 94 (46.1) 87 (49.4)
NOTE.—Hardy-Weinberg equilibrium (HWE) of p53 genotypes was
assessed by exact tests. Both groups were in HWE: younger controls,
; and centenarians, . x2 tests for comparison of allelicP  .46 P  .61
and genotypic distributions were performed by use of Monte Carlo
algorithms implemented by means of the Statistical Product and Service
Solutions package.
a , df 1, .2x  0.64 P  .42
b , df 2, .2x  0.74 P  .68
bold 1997). Second, we can assume that p53 codon 72
Arg/Pro alleles are not neutral. In view of this hypothesis,
our data on healthy centenarians suggest that the long-
term consequences of p53 codon 72 Arg/Pro alleles on
survival are negligible, even though they are related to
increased cancer risk. However, additional data regard-
ing the incidence of and mortality rate for p53-related
cancers in the cohort studied and the relative risk of
developing these diseases, for different p53 allelic vari-
ants, are needed in order to reject the above-mentioned
hypothesis. On the other hand, recent data indicate that
p53 polymorphisms appear to modulate an individual’s
risk of developing cancer only when peculiar conditions
occur (i.e., a particular viral infection). In this case, only
a small proportion of people who carry certain alleles
would be selectively lost during aging.
However, these considerations probably are quite sim-
plistic, owing to the possibility that the scenario is much
more complex. Indeed, unexpected nonmonotonic age-
related trends of allele frequency can be found for genes
related to survival and longevity. This is the case for the
ApoB gene (De Benedictis et al. 1998), which we pre-
viously showed to be correlated with longevity (De Bene-
dictis et al. 1997). We recently conceptualized these find-
ings and created a model to account for the complex
changes, with age, observed for ApoB gene allele fre-
quencies (Yashin et al. 1998). According to this model,
complex trajectories can be expected when the existence
of “frail” and “robust” alleles of longevity-associated
genes are assumed and when the mortality rates of the
carriers of the two types of alleles are crossed. A similar
conclusion was reached when changes, with age, in the
allelic frequencies of genes related to cardiovascular risk
factors, such as angiotensin-converting enzyme, were
considered (Schachter et al. 1994).
As far as we know, the above-mentioned models
(Toupance et al. 1998; Yashin et al. 1998) represent the
only theoretical framework available to address the com-
plex problems encountered when biodemographic data
and genetic data, concerning longevity genes and genes
related to risk factors for major age-related diseases, are
merged and compared. A similar model for p53 could
be of great interest and could help in (1) testing the
hypothesis that the p53 Arg/Pro72 alleles are related to
increased cancer risk and (2) answering the question of
whether the frequency of the p53 alleles that we found
in centenarians is compatible with this hypothesis. We
predict that such a model will be quite difficult to de-
velop, given that p53 is involved in a variety of tumors
and that there is a relative paucity of data on p53 allele
frequencies in people of different age groups and, par-
ticularly, in the elderly.
In this regard, if we admit that the data reported here
imply no global differential chance of survival between
p53 genotypes, our results could be due to compensatory
effects. Indeed, opposite effects of genotypes on survival,
at different ages, are predicted by the theory of negative,
or antagonistic, pleiotropy (Williams 1957). The sce-
nario is particularly interesting and challenging with re-
gard to the healthy centenarians, who are the best mod-
els of successful aging and longevity and in whom a
variety of other genetic and nongenetic risk factors for
cardiovascular diseases was found (Mari et al. 1996;
Mannucci et al. 1997; Baggio et al. 1998). Furthermore,
healthy centenarians also can rely on other compensa-
tory mechanisms, such as an effective and well-preserved
immune system, to cope with internal and external
threatening agents (Franceschi et al. 1995).
In conclusion, healthy centenarians may be considered
useful models for testing basic theories on aging. More-
over, this selected group of healthy individuals will be
useful for evaluating the impact of genetic risk factors
on survival and longevity.
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